Seroprevalence of hepatitis B viral markers among freshmen - 20 years after mass hepatitis B vaccination program in Taiwan

Journal of the Formosan Medical Association

Volumn 106, Issue 7, 2007, Pages 513-519

  Chang, Hsien Cheng ^b   Yen, Chung Jen ^a   Lee, Yi Chin ^a   Chiu, Tai Yuan ^b   Jan, Chyi Feng ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatitis B; Seroprevalence; Taiwan; Vaccination; Youth

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FAMILY HISTORY; FEMALE; FOLLOW UP; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; QUESTIONNAIRE; SELF REPORT; SEROPREVALENCE; SEX; STATISTICAL SIGNIFICANCE; TAIWAN; UNIVERSITY STUDENT; VIRUS CARRIER;

EID: 34547904285     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(07)60001-1     Document Type: Article

References (24)

1. Chen DS, Sung JL. Hepatitis B virus infection in Taiwan. N Engl J Med 1977;297:668-9.
2. Chen DS, Sung JL, Lai MY. A seroepidemiologic study of hepatitis B virus infection in Taiwan. Taiwan Yi Xue Hui Za Zhi 1978;77:908-18.
3. Ni YH, Chang MH, Hsu HY, et al. Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer 1991;68:1737-41.
4. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129-33.
5. Chang MH, Chen DS, Hsu HC, et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64:2377-80.
6. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-5.
7. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257:2597-603.
8. Hsu HM, Lu CF, Lee SC, et al. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999;179: 367-70.
9. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
10. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
11. Chen HL, Chang CJ, Kong MS, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004;39:58-63.
12. Kao JH, Hsu HM, Shau WY, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52.
13. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800.
14. Lin HH, Wang LY, Hu CT, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003;69:471-4.
15. Lu SN, Chen CH, Chen TM, et al. Hepatitis B virus infection in adolescents in a rural township - 15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 2005;24: 759-65.
16. Chien YC, Jan CF, Kuo HS, et al. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28: 126-35.
17. Liu JH, Lu SN, Ho CK, et al. Changes of hepatitis B markers among young adults in a hepatitis B virus endemic area: a follow up study on medical students. Kaohsiung J Med Sci 1997;13:286-92.
18. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
19. Fitzsimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23:4158-66.
20. John TJ, Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J Gastroenterol Hepatol 2005;20:5-10.
21. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004;40:1415-20.
22. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
23. Lo KJ, Tsai YT Lee SD, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985; 152:817-22.
24. Lo KJ, Tsai YT, Lee SD, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology 1985; 32:65-8.